Patient Support Resources | MVASI® (bevacizumab-awwb)

INDICATIONS

Metastatic Colorectal Cancer (mCRC)

MVASI^® is approved to treat metastatic colorectal cancer (mCRC) for:

First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI^®

MVASI^® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

MVASI^®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (rGBM)

MVASI^® is approved to treat recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

MVASI^®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Advanced Cervical Cancer (CC)

MVASI^®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Supportplus

Supportplus

We're right here, right when you need us

Personalized patient support designed for you.

Call Amgen^® SupportPlus
at 866-264-2778

Monday through Friday —
9:00 AM to 8:00 PM ET

Visit AmgenSupportPlus.com to learn how Amgen can help.

Amgen^® SupportPlus Co-Pay Program*

**If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible to pay as little as $0* for your prescription.**

Pay as little as $0* out-of-pocket for each dose
Can be applied to deductible, co-insurance, and co-payment*
No income eligibility requirement

amgen-support-plus-medical-card

amgen-support-plus-medical-card

Check your eligibility and sign up today at AmgenSupportPlus.com/copay

*
Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/Copay for full Terms and Conditions.

What if I don’t have private or commercial insurance
(eg, self-purchased or through an employer)?

Amgen^® SupportPlus can provide information about independent nonprofit foundations that may be able to help.^†

Call Amgen^® SupportPlus at 866-264-2778 Monday - Friday 9:00am – 8:00pm ET to learn more.

^†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.

For information on any of these
programs, connect with us at

Call 866-264-2778

AmgenSupportPlus.com

Monday through Friday - 9:00 AM to
8:00 PM ET

Patient Brochure

TO LEARN MORE ABOUT YOUR CANCER AND MVASI^®, DOWNLOAD THIS BROCHURE

Patient Brochure

FOR INFORMATION SPECIFIC TO YOUR DIAGNOSIS, PLEASE MAKE A SELECTION BELOW

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
COLORECTAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
NON-SMALL CELL LUNG CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
GLIOBLASTOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
RENAL CELL CARCINOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
CERVICAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI^® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
OVARIAN CANCER

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT
VARIOUS CANCERS

IMPORTANT SAFETY INFORMATION

Possible serious side effects

Everyone reacts differently to MVASI^® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.

GI perforation. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
Abnormal passage in the body. This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
Wounds that don't heal. A cut made during surgery can be slow to heal or may not fully heal. MVASI^® should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed
Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor
Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on MVASI^® and after stopping treatment
Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
Infusion-related reactions. These were uncommon with the first dose (less than 3% of patients). 0.4% of patients had severe reactions. Infusion-related reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion-related reactions
Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

High blood pressure
Too much protein in the urine
Nosebleeds
Bleeding
Back pain
Headache

Taste change
Dry skin
Inflammation of the skin
Inflammation of the nose
Watery eyes

MVASI^® is not for everyone

Talk to your doctor if you are:

Undergoing surgery. MVASI^® should not be used for 28 days before or after surgery and until surgical wounds are fully healed
Pregnant or think you are pregnant. Data have shown that MVASI^® may harm your unborn baby. Use birth control while on MVASI^®. If you stop MVASI^®, you should keep using birth control for 6 months before trying to become pregnant
Planning to become pregnant. Taking MVASI^® could cause a woman’s ovaries to stop working and may impair her ability to have children
Breastfeeding. Breastfeeding while on MVASI^® may harm your baby, therefore, women should not breastfeed during and for 6 months after taking MVASI^®

For more information about your treatment or condition, talk to your doctor.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.

Please see full Product Information for additional Important Safety Information.

INDICATIONS

Metastatic Colorectal Cancer (mCRC)

MVASI^® is approved to treat metastatic colorectal cancer (mCRC) for:

First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI^®

MVASI^® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

MVASI^®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (rGBM)

MVASI^® is approved to treat recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

MVASI^®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Advanced Cervical Cancer (CC)

MVASI^®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Ovarian Cancer (OC)

MVASI^®, in combination with carboplatin and paclitaxel, followed by MVASI^® alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.

MVASI^®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.

MVASI^®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by MVASI^® alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

MVASI^® is a trademark of Amgen, Inc.